What Does Bx Mean in Medical Terms?

Bx is the standard medical abbreviation for biopsy, a procedure in which a small sample of tissue is removed from the body so it can be examined under a microscope. You will see “Bx” written in clinical notes, radiology reports, and pathology orders, and it almost always refers to the same thing: taking a piece of tissue to figure out what is going on at a cellular level. While blood tests and imaging scans can raise suspicion about a disease, a biopsy often provides the definitive answer, particularly in cancer diagnosis where it remains the gold standard for confirming whether abnormal cells are present.

Why Biopsies Are Ordered

Doctors order a Bx when they need to know the exact nature of a lump, lesion, or area of abnormal tissue. The most common reason is to determine whether something is cancerous or benign, but biopsies also play a central role in diagnosing autoimmune diseases, infections, organ rejection after transplant, and inflammatory conditions like celiac disease. For celiac disease specifically, intestinal biopsy has long been considered the gold standard for confirming the diagnosis.¹ Kidney biopsies help nephrologists distinguish between different types of kidney disease that look identical on lab work. Liver biopsies assess the degree of scarring in chronic liver disease. In short, a biopsy is ordered whenever the diagnosis depends on seeing the tissue itself, not just measuring something in the blood or taking a picture from the outside.

Needle Biopsies and How They Differ

When most people hear “biopsy,” they picture a needle being inserted through the skin. That covers a large share of biopsies performed today, but there are two quite different needle approaches, and understanding the distinction matters because it affects what your doctor can learn from the sample.

Fine-needle aspiration (FNA) uses a thin needle, often guided by ultrasound, to suction out a small cluster of cells. It is quick, causes minimal discomfort, and works well for certain situations like draining cysts, sampling suspicious lymph nodes, or checking a thyroid nodule. The downside is that FNA collects loose cells rather than an intact piece of tissue, which limits what a pathologist can determine. FNA cannot reliably distinguish between certain types of cancer that look similar at the cellular level, and it produces a higher rate of inconclusive results compared to the alternative.²

Core needle biopsy (CNB) uses a slightly larger, spring-loaded needle to cut and retrieve a small cylinder of tissue. Because the sample preserves the tissue’s architecture, pathologists can see how cells are organized relative to each other, which is critical for grading cancers and testing for specific molecular markers. For breast lesions, core needle biopsy has largely replaced FNA as the standard first-line diagnostic tool because it more frequently yields a definitive diagnosis for both benign and malignant findings.² It also provides enough material to test for hormone receptors and genetic mutations that guide treatment decisions.³

That said, FNA still has clear roles. It remains the preferred method for cystic lesions that are mostly fluid, for sampling spots on the chest wall when cancer recurrence is suspected, and for checking whether cancer has spread to nearby lymph nodes.² The choice between the two is not about one being universally better; it depends on what the doctor needs to learn and where in the body the sample is coming from.

Surgical and Endoscopic Biopsies

Not all biopsies go through the skin. When a suspicious area sits along the lining of the digestive tract, bladder, or airways, an endoscopic biopsy is often the simplest approach. A flexible scope is threaded in through a natural opening, and tiny forceps at the tip snip off fragments of tissue. This is routine during colonoscopies, upper endoscopies, and bronchoscopies. In some cases, though, standard endoscopic biopsies cannot reach deep enough. For gastric wall thickening where conventional biopsies come back negative, specialized techniques guided by endoscopic ultrasound can tunnel beneath the surface lining to sample deeper tissue layers.⁴

Surgical biopsies, which involve cutting through skin under local or general anesthesia, are reserved for situations where needle approaches cannot get a large enough or representative enough sample. An incisional biopsy removes a portion of a mass; an excisional biopsy removes the entire thing. Excisional biopsies double as treatment when the whole abnormal area is taken out in one go, which is common with suspicious skin lesions and some small breast lumps. Surgical biopsies are more invasive, carry higher costs, and require more recovery time, so they tend to be a second step when a less invasive biopsy was inconclusive or when the location of the mass makes needle access impractical.

What Happens to Your Sample Afterward

Once tissue leaves your body, it enters the pathology lab, and the processing steps explain why results do not come back instantly. The sample is first preserved in a fixative, typically formalin, to prevent the cells from breaking down. It is then dehydrated, cleared of water and fat, and infiltrated with paraffin wax so it becomes solid enough to be sliced into sections thinner than a sheet of paper.⁵ Those ultra-thin slices are mounted on glass slides and stained with dyes that highlight different structures within the cells. A pathologist then examines the stained slides under a microscope and writes a report describing what they see.

For straightforward cases, this process takes a few business days. More complex cases may require additional staining techniques, molecular testing, or review by a subspecialty pathologist, all of which extend the timeline. Delays often occur at specific bottlenecks like slide delivery, pathologist review, and report editing rather than in the tissue processing itself.⁶ If your doctor says results will take one to two weeks, that usually reflects the combination of lab processing, pathologist workload, and any special tests that need to run.

When a Biopsy Gets It Wrong

Biopsies are highly accurate, but they are not infallible. A false negative means the biopsy comes back benign when the tissue is actually cancerous, and this happens for a few reasons. The most straightforward is a sampling miss: the needle did not land squarely in the abnormal area. This can happen when the lesion is small, located deep near the chest wall, or difficult to see on imaging. A retrospective analysis of nearly a thousand breast core needle biopsies found that sampling from the wrong site and poor visualization of the lesion or needle were among the most common causes of false negatives.⁷

A more subtle problem is tumor heterogeneity. A cancerous mass is not uniform throughout; it can contain regions of dead tissue, scar tissue, inflammation, and normal cells mixed in with malignant ones. If the needle happens to sample one of those non-cancerous pockets, the pathologist sees only benign tissue. The same analysis identified this kind of heterogeneity as the probable cause of a false negative even when ten separate tissue sections were collected.⁷ This is why doctors sometimes recommend a repeat biopsy or a surgical biopsy when imaging findings remain suspicious despite a benign needle biopsy result.

Risks and Complications

The most common complication from a needle biopsy is bleeding at the puncture site, followed by pain or bruising. In a study of ultrasound-guided liver biopsies, about one in twenty patients experienced some degree of bleeding, though the vast majority of those cases resolved with simple compression and did not require further treatment.⁸ Roughly one in five patients in that study reported pain afterward, but none developed serious secondary complications like collapsed lung or infection. Major bleeding requiring intervention occurred in under one percent of cases.⁸

A concern that frequently worries patients is needle tract seeding, the idea that pushing a needle through a tumor could drag cancer cells along the needle path and spread them to healthy tissue. While cell displacement along the needle track does occur at a microscopic level, it is a rare event clinically and does not appear to affect long-term survival.⁹ The risk receives outsized attention in patient discussions relative to how often it actually causes a problem.¹⁰ Doctors use coaxial needle techniques and careful path planning to minimize the possibility further. If you are worried about this, it is worth asking your doctor about it, but it should not be a reason to refuse a biopsy that your care team considers important.

The Anxiety of Waiting for Results

The days between having a biopsy and receiving results are among the most stressful in a patient’s medical experience. Research consistently shows that the period of uncertainty can be harder on people psychologically than actually receiving bad news. Studies have found elevated stress hormone levels in patients awaiting biopsy results, and that anxiety tends to drop significantly once results are delivered, regardless of what those results say.¹¹ The uncertainty itself is the worst part for many people.

How your doctor communicates before and during the procedure also makes a measurable difference. A study of women undergoing imaging-guided breast biopsy found that better communication from the radiologist who recommended the biopsy was linked to lower pre-procedure anxiety, and that strong communication from the radiologist performing the biopsy predicted lower anxiety afterward as well.¹² If you feel anxious going into a biopsy, asking your doctor to walk you through what will happen and what the possible outcomes are is not a trivial request. It has a real effect on how you feel during and after the procedure.

How Much Biopsies Cost

Biopsy costs vary enormously depending on whether the procedure is done as an outpatient needle biopsy or an inpatient surgical procedure. A study of lung cancer patients in the United States found that outpatient needle biopsies had median total costs around $1,000, while inpatient surgical biopsies ran close to $30,000.¹³ Repeat biopsies of the same type drove costs up by 40 to 80 percent, and complications accounted for about 13 percent of total biopsy-related spending.¹³ Those numbers help explain why getting an adequate sample on the first attempt is a priority for everyone involved: the financial burden of a do-over is substantial, on top of the stress and physical toll on the patient.

Liquid Biopsy and the Move Away from Needles

One of the most talked-about developments in diagnostics is the liquid biopsy, which analyzes a standard blood draw rather than a tissue sample. Instead of retrieving cells from a tumor, liquid biopsies look for fragments of tumor DNA and intact tumor cells that have shed into the bloodstream. This approach has attracted enormous clinical interest because it can potentially detect cancer, predict prognosis, monitor how well a treatment is working, and identify when a cancer has developed resistance to a drug, all from a tube of blood.¹⁴

Liquid biopsies are already in clinical use for certain applications, particularly for tracking treatment response in patients with known advanced cancers. They are less invasive, easily repeatable, and can capture genetic information from tumors that are difficult or dangerous to biopsy with a needle. However, liquid biopsies have not replaced traditional tissue biopsies for initial cancer diagnosis in most situations. The concentration of tumor material in the blood can be extremely low, especially in early-stage cancers, and a tissue biopsy still provides the architectural detail and molecular profiling that treatment planning depends on. Think of liquid biopsy as a powerful complement to traditional Bx rather than a replacement, at least for now.

Artificial Intelligence in Biopsy Analysis

Pathology has traditionally depended entirely on a human expert looking at stained tissue under a microscope. That is changing. Whole slide imaging now digitizes biopsy slides at very high resolution, and artificial intelligence systems trained on thousands of cases can assist pathologists in identifying abnormal areas. A large systematic review and meta-analysis of AI applied to digitized biopsy slides found that these systems achieved a mean sensitivity of about 96 percent and a mean specificity of about 93 percent across a range of disease types.¹⁵

Those are impressive numbers, but they come with context. Most AI studies to date have been conducted in controlled research settings rather than in the messy reality of everyday clinical practice. The same review noted that more rigorous real-world evaluation is still needed before AI pathology tools become part of routine care everywhere.¹⁵ Where AI is likely to have its earliest and largest impact is in reducing the workload on pathologists, who face growing caseloads, and in flagging areas of a slide that deserve closer attention. The technology is not about removing the human from the loop but about making the human faster and less likely to miss something subtle in a large or complex sample.

Biopsies in Veterinary Medicine

If you have ever had a pet undergo a biopsy, you might wonder whether the same principles apply. They largely do. Veterinarians use fine-needle aspirates, core needle biopsies, and surgical biopsies in dogs and cats for many of the same reasons human doctors do: to diagnose tumors, inflammatory diseases, and organ dysfunction. The challenges are similar as well. A study comparing different liver biopsy sampling techniques in dogs found that needle, cup, and punch biopsy methods agreed with the definitive diagnosis roughly 60 to 69 percent of the time, with no one method clearly outperforming the others.¹⁶

Grading accuracy is a particular concern in veterinary oncology. A study of soft tissue sarcomas in dogs found that pre-treatment biopsies, whether needle core or open wedge, agreed with the final excisional biopsy grade only about 59 percent of the time. When the two disagreed, the pre-treatment biopsy was more likely to underestimate the tumor’s aggressiveness than to overestimate it.¹⁷ Veterinarians face the same sampling limitations that human pathologists do: a needle can only capture a tiny sliver of a mass, and tumors are not homogeneous. If your vet recommends a biopsy for your pet and later suggests a follow-up procedure because the first sample was inconclusive, the reasons are the same ones that apply in human medicine.

1
Elsevier / Gastroenterology. Biopsy is the gold standard of diagnosis of celiac sprue
2
PubMed Central. Fine-needle versus core-needle biopsy – which one to choose in preoperative assessment of focal lesions in the breasts? Literature review
3
PubMed. Fine-needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities
4
PubMed Central. EUS-guided sampling for the diagnosis of conventional endoscopic biopsy-negative gastric wall thickening
5
PubMed. Tissue processing and hematoxylin and eosin staining
6
PubMed Central. Reducing turnaround time of surgical pathology reports in pathology and laboratory medicine departments
7
PubMed Central. False-negative results of breast core needle biopsies – retrospective analysis of 988 biopsies
8
PubMed Central. Risk of needle tract seeding after coaxial ultrasound-guided percutaneous biopsy for primary and metastatic tumors of the liver
9
PubMed Central. Reducing the Risk of Needle Tract Seeding or Tumor Cell Dissemination during Needle Biopsy Procedures
10
PubMed. Tumour seeding following percutaneous needle biopsy: the real story!
11
PubMed Central. Awaiting Pathology: From Oncology Clinician to Oncology Patient
12
PubMed. Patient Anxiety Before and Immediately After Imaging-Guided Breast Biopsy Procedures: Impact of Radiologist-Patient Communication
13
ClinicoEconomics and Outcomes Research. Costs of Biopsy and Complications in Patients with Lung Cancer
14
PubMed. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
15
PubMed Central. Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy
16
PubMed Central. A Comparison of Liver Sampling Techniques in Dogs
17
PubMed. Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs